XFOR Insider Trading

Insider Ownership Percentage: 1.62%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $412,578.00

X4 Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at X4 Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$400k-$200k$0$200k$400kTotal Insider BuyingTotal Insider Selling

X4 Pharmaceuticals Share Price & Price History

Current Price: $4.35
Price Change: Price Decrease of -0.99 (-18.54%)
As of 04/29/2025 05:00 PM ET

This chart shows the closing price history over time for XFOR up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
JunJulAugSepOctNovDecJanFebMarApr$4.35Closing price on 04/29/25:

SEC Filings (Institutional Ownership Changes) for X4 Pharmaceuticals (NASDAQ:XFOR)

72.03% of X4 Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at XFOR by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$38Mbought$4.58MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$50M$0$50MTotal InflowsTotal Outflows
X4 Pharmaceuticals logo
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.
Read More on X4 Pharmaceuticals

Today's Range

Now: $4.35
Low: $4.17
High: $5.50

50 Day Range

MA: $8.25
Low: $4.35
High: $14.01

52 Week Range

Now: $4.35
Low: $4.18
High: $36.60

Volume

308,498 shs

Average Volume

90,272 shs

Market Capitalization

$755.43 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.58

Who are the company insiders with the largest holdings of X4 Pharmaceuticals?

X4 Pharmaceuticals' top insider shareholders include:
  1. Paula Ragan (CEO)
  2. Mary Dibiase (COO)
  3. Arthur Taveras (Insider)
  4. Tuvia Barlev (CEO)
  5. Murray Stewart (Insider)
  6. Mark Baldry (Insider)
  7. Adam S Mostafa (CFO)
  8. Michael S Wyzga (Director)
  9. Israel Niv (Director)
  10. Adam S Mostafa (CFO)
Learn More about top insider investors at X4 Pharmaceuticals.